Drug Sponsors

Orgentec Diagnostika to acquire Corgenix

Friday, August 29, 2014 10:32 AM

Corgenix Medical, a Colorado-based, worldwide developer and marketer of diagnostic test kits, has agreed to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany. The strategic acquisition will extend both companies’ global distribution networks and broaden their portfoliod of specialty diagnostic assays.

More... »


Report: Pharma crosses new frontiers with global tiered pricing strategies

Wednesday, August 27, 2014 01:15 PM

Despite the adoption of tiered pricing strategies by pharmaceutical companies around the world, there is only a tenuous correlation between the prices of pharmaceutical products and the local economic conditions of the countries where they are launched, according to a comprehensive new study by IHS, a global source of critical information and insight, headquartered in Englewood, Colo.

More... »


Cilag International acquires Covagen

Wednesday, August 27, 2014 01:13 PM

Cilag International, a Switzerland-based affiliate of Janssen Pharmaceutical, a division of Johnson & Johnson, has acquired Covagen, a privately held biopharmaceutical company specializing in the development of multi-specific protein therapeutics through the FynomAb technology platform.

More... »

Medtronic acquires Sapiens Steering Brain Stimulation

Wednesday, August 27, 2014 01:12 PM

Medtronic, a Minneapolis, Minn., medical technology provider, has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a Netherlands-based, privately held developer of deep brain stimulation (DBS) technologies, for approximately $200 million in cash.

More... »

Covidien acquires Reverse Medical

Monday, August 25, 2014 02:11 PM

Covidien, a Dublin, Ireland-based global healthcare products company and manufacturer of medical devices and supplies, has acquired California-based Reverse Medical, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction have not been disclosed.

More... »

Roche to acquire InterMune for $8.3 billion

Monday, August 25, 2014 02:02 PM

Roche and InterMune have entered into a definitive merger agreement under which Roche will fully acquire InterMune for $74 per share in cash, for a total transaction value of $8.3 billion on a fully diluted basis.

More... »

Pfizer, Gamida Cell ink investment and option agreement

Wednesday, August 20, 2014 01:31 PM

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

More... »

Valeant extends offer to acquire Allergan

Wednesday, August 20, 2014 01:26 PM

Valeant Pharmaceuticals International has extended the expiration of its exchange offer to acquire all outstanding shares of Allergan to 5:00 p.m., New York City time, Dec. 31. The exchange offer previously was scheduled to expire at 5:00 p.m., New York City time, Friday, Aug. 15. All other terms and conditions of the exchange offer remain unchanged.

More... »

Nanotherapeutics opens new office in Maryland

Wednesday, August 20, 2014 01:17 PM

Nanotherapeutics, an integrated biopharmaceutical company with a focus on development and manufacturing, has opened a new office in Frederick, Md. The office was established to better support the company’s U.S. government contracts. With headquarters in Alachua, Fla., and a clinical team in Durham, N.C., Nanotherapeutics now has three strategically located offices.

More... »

Group of 19 institutional investors seeks support for biosimilars from top biopharma companies

Thursday, August 14, 2014 02:34 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Don’t bad mouth biosimilars—they are needed to help hold down skyrocketing drug costs.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs